|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Wagner, J. A., S. A. Williams, and C. J. Webster. 2007. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clinical Pharmacology and Therapeutics 81(1):104–107. Wang, Y., and J. M. G. Taylor. 2002. A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 58(4):803–812. Webb, K. S., and G. H. Lin. 1980. Urinary fibronectin—Potential as a biomarker in prostatic-cancer. Investigative Urology 17(5):401–404. Weir, C. J., and R. J. Walley. 2006. Statistical evaluation of biomarkers as surrogate endpoints: A literature review. Statistics in Medicine 25(2):183–203. Wittes, J., E. Lakatos, and J. Probstfield. 1989. Surrogate endpoints in clinical trials: Cardiovascular diseases. Statistics in Medicine 8(4):415–425. Wood, P. H. 1983. Where are we now with radiographic assessment of rheumatoid arthritis? British Journal of Rheumatology 22(3 Suppl):24–33. Woosley, R. L. 1990. CAST—Implications for drug development—Commentary. Clinical Pharmacology & Therapeutics 47(5):553–556. Xu, J., and S. L. Zeger. 2001. The evaluation of multiple surrogate endpoints. Biometrics 57(1):81–87.
|
|
|||||||||||||||
